New Hope for Pancreatic Cancer Treatment with LODER™
Silexion Therapeutics Corp. (NASDAQ: SLXN) has unveiled exciting results from its Phase 2 trial of LODER™, aimed at patients with non-resectable locally advanced pancreatic cancer (LAPC). The analysis reveals an impressive objective response rate (ORR) of 56% for those treated with LODER, and even higher at 67% for patients whose tumors became resectable after therapy. This research marks a major advancement in improving surgical outcomes for pancreatic cancer patients, especially those with KRAS G12D and G12V mutations, which are present in about 70% of cases.
Enhancing Surgical Options with LODER™
Earlier data showed that patients receiving LODER alongside standard chemotherapy had an increase in overall survival by 9.3 months compared to those who received chemotherapy alone. The latest findings underscore LODER's potential not just as a treatment, but also as a means to convert non-resectable tumors into resectable ones, opening new surgical possibilities for individuals battling this challenging cancer.
Next Generation Innovation: SIL-204
Silexion is progressing with its innovative pipeline, introducing SIL-204, a next-generation product designed to enhance its effectiveness against a broader range of KRAS mutations. This development aims to tackle pan-G12x and G13D mutations and is expected to offer unique benefits in terms of stability and targeted delivery to tumors, effectively silencing the oncogenic KRAS. The advantages indicated in preclinical studies provide a hopeful outlook for treating difficult cancers associated with KRAS, including locally advanced pancreatic cancer.
Leadership Insights
"We are truly encouraged by these findings, as they highlight LODER's effectiveness in increasing tumor resectability for patients with challenging pancreatic cancers," Ilan Hadar, Chairman and CEO of Silexion, stated. "As we expand our pipeline, this data reinforces our approach to oncogene silencing, demonstrating our commitment to addressing KRAS-driven cancers directly."
Understanding the Phase 2 Trial of LODER
The open-label Phase 2 trial included 48 participants from the modified intent-to-treat (mITT) population, specifically targeting those with non-resectable LAPC and borderline resectable pancreatic cancer (BRPC). Conducted at various sites, the trial was structured into two distinct cohorts.
Cohort Structure and Patient Involvement
Cohort 1 contained 29 patients randomly assigned to receive either LODER combined with standard-of-care chemotherapy or chemotherapy alone. This arm's primary goal was to assess overall survival, with 16 participants confirmed to have the KRAS G12D/V mutation. Meanwhile, Cohort 2 included 19 participants with non-resectable LAPC or BRPC, focusing primarily on the ORR and safety of LODER. Among these patients, seven had confirmed KRAS mutations.
About Silexion Therapeutics
Silexion Therapeutics (NASDAQ: SLXN) is a trailblazer in creating RNA interference (RNAi) therapies targeting solid tumors driven by KRAS mutations, which are one of the most common oncogenic factors in serious cancers today. Their leading product, LODER, has shown promising results in the Phase 2 trial for non-resectable pancreatic cancer, establishing the company as a frontrunner in innovative cancer therapies. Silexion's dedication to advancing its siRNA candidate, SIL-204, illustrates its ambition to address a wider range of KRAS mutations. Through ongoing research and development, Silexion is committed to transforming cancer care and striving for better outcomes for patients facing tough malignancies.
Frequently Asked Questions
What is LODER™ and how does it work?
LODER™ is a groundbreaking therapy developed by Silexion that uses RNA interference (RNAi) technology to target and silence KRAS mutations in pancreatic cancer, aiming to enhance treatment outcomes for patients.
What were the key results from the Phase 2 trial of LODER?
The Phase 2 trial showed that there is a 56% objective response rate for patients treated with LODER, which rises to 67% for those whose tumors became resectable due to treatment.
What is SIL-204?
SIL-204 represents Silexion’s next-generation therapeutic candidate, focusing on targeting a broader array of KRAS mutations and demonstrating promising potential in preclinical studies for tackling challenging cancers.
How does Silexion plan to enhance patient outcomes?
Silexion aims to improve patient outcomes by developing innovative treatments specifically aimed at KRAS mutations, with ongoing research to enhance treatment effectiveness and expand surgical options for patients.
What is the significance of the findings for patients with pancreatic cancer?
The results from the LODER trial represent a significant step forward in pancreatic cancer treatment, particularly for patients with formerly non-resectable tumors, potentially giving them a better chance for surgical intervention.
